| dc.creator | Silva, Gilberto Marcelo Sperandio da | |
| dc.date | 2022-11-16T19:08:10Z | |
| dc.date | 2022-11-16T19:08:10Z | |
| dc.date | 2022 | |
| dc.date.accessioned | 2023-09-26T21:10:43Z | |
| dc.date.available | 2023-09-26T21:10:43Z | |
| dc.identifier | SILVA, Gilberto Marcelo Sperandio. Traditional use of benznidazole with weekly clinical follow-up indicate to be an important approach for the etiologic treatment of Chagas disease. Memorias do Instituto Oswaldo Cruz, v. 117, p. 1-2, 2022. | |
| dc.identifier | 0074-0276 | |
| dc.identifier | https://www.arca.fiocruz.br/handle/icict/55661 | |
| dc.identifier | 10.1590/0074-02760210034chgsa | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8870392 | |
| dc.description | Despite more than 100 years of the description of Chagas disease (CD), it still affects about 6 to 7 million people
worldwide, most of them, about 6 million in Latin America. The CD estimated prevalence in
Brazil for 2020 is about 1.3 to 3.2 million individuals. CD can be associated with situations of poverty, when the kissing bug invades the house and feeds on the human
host, infecting it with the flagellate protozoan Trypanosoma cruzi, the agent of CD. In general, benznidazole (BZN) is the most used drug for etiologic treatment in Brazil, indicated for all age
groups when the patient is in the acute phase and, in the chronic phase, for individuals under 50 years of age without
advanced heart disease. Nifurtimox (NFx) would be an alternative for patients who are intolerant to BZN. | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.publisher | Scielo | |
| dc.rights | open access | |
| dc.subject | Chagas disease | |
| dc.subject | Benznidazole | |
| dc.subject | Treatment | |
| dc.title | Traditional use of benznidazole with weekly clinical follow-up indicate to be an important approach for the etiologic treatment of Chagas disease | |
| dc.type | Article | |
